Back to Search
Start Over
Candidacy of adult patients with short bowel syndrome for treatment with glucagon-like peptide-2 analogues: A systematic analysis of a single centre cohort
- Publication Year :
- 2021
-
Abstract
- Summary Background and aims The glucagon-like peptide-2 (GLP-2) analogue, teduglutide, allows to reduce the intravenous supplementation (IVS) dependency of patients with short bowel syndrome and intestinal failure (SBS-IF). The rate of candidacy of SBS-IF patients for the treatment is unknown. The candidacy for teduglutide treatment of our patient cohort was investigated by a systematic analysis. Methods The indications, contraindications, special warnings and precautions for use of teduglutide, listed in the drug monographs and in the phase-III trial protocol were adopted to categorize the patients as non-candidates (NC), potential candidates (PC) or straight candidates (SC) for the treatment. All the SBS-IF adult patients who were cured at our centre were assessed according to their clinical status on January 1st, 2020. Results Seventy-nine patients were evaluated: 34.2% were NC due to risk of digestive malignancy, recent history of any other cancer, or listing for intestinal transplantation; 30.4% were PC, because of other premalignant conditions, risk of intestinal obstruction, entero-cutaneous fistulas, or severe co-morbidities; 35.4% were SC. The SC group showed the lowest requirement of IVS: the lowest number of days of infusion per week (p = 0.0054), the lowest amount of energy (p = 0.0110) and volume (p = 0.0136). Conclusions This systematic analysis allowed a pragmatic categorization of the candidacy of patients with SBS-IF for GLP-2 analogue treatment. The SC group appeared to have the highest probability of a successful response to the treatment. A systematic analysis of SBS-IF patient candidate for GLP-2 analogue therapy would allow a homogeneous patient selection and facilitate the worldwide comparison of the results of clinical practice and research.
- Subjects :
- 0301 basic medicine
Male
Short Bowel Syndrome
medicine.medical_specialty
030209 endocrinology & metabolism
Critical Care and Intensive Care Medicine
Malignancy
Teduglutide
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Gastrointestinal Agents
Internal medicine
Gastrointestinal Agent
medicine
Humans
Prospective Studies
Aged
Cross-Sectional Studie
Home parenteral nutrition
030109 nutrition & dietetics
Nutrition and Dietetics
business.industry
Patient Selection
Cancer
Intestinal failure
Middle Aged
Short bowel syndrome
medicine.disease
Glucagon-like peptide-2
Intestinal transplantation
Intravenous supplementation
Transplantation
Prospective Studie
Cross-Sectional Studies
chemistry
Clinical Trials, Phase III as Topic
Italy
Cohort
Peptide
Candidacy
Female
GLP-2 analogue
business
Peptides
Human
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....9e17826e6eecd973f378b3082a7fef71